Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, ti... Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator. Mehr anzeigen
Viking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024 PR Newswire SAN DIEGO, Nov. 19, 2024 Oral Late Breaker...
Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024 PR Newswire SAN DIEGO, Nov. 12, 2024 Results...
Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek® 2024 PR Newswire SAN DIEGO, Nov. 4, 2024 Up to 6.8% Placebo-Adjusted Mean Weight Loss (8.2% from Baseline) After...
Viking Therapeutics to Participate at Upcoming Investor Conferences PR Newswire SAN DIEGO, Oct. 31, 2024 SAN DIEGO, Oct. 31, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:...
Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2024 PR Newswire SAN DIEGO, Oct. 28, 2024 Results from VENTURE Phase 2 Study of...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 4.65 | 9.53846153846 | 48.75 | 54.2799 | 47.85 | 3454225 | 51.87762366 | CS |
| 4 | -20.6 | -27.8378378378 | 74 | 79.1 | 47.6501 | 5846450 | 60.51034492 | CS |
| 12 | -10.12 | -15.9319899244 | 63.52 | 81.7295 | 47.6501 | 4183227 | 63.36077967 | CS |
| 26 | -10.06 | -15.8525055153 | 63.46 | 81.7295 | 46.11 | 3921540 | 60.51103573 | CS |
| 52 | 41.15 | 335.918367347 | 12.25 | 99.3999 | 11.545 | 4340450 | 59.83707539 | CS |
| 156 | 47.9 | 870.909090909 | 5.5 | 99.3999 | 2.02 | 2855087 | 35.94014987 | CS |
| 260 | 46.2 | 641.666666667 | 7.2 | 99.3999 | 2.02 | 2175039 | 29.56229376 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
